CYBB and acute myeloid leukemia: However, phase III trial results showed that the combination of HDC and low-dose IL-2 improves the leukemia-free survival (LFS) of AML patients in complete remission (CR) after chemotherapy [32], thus supporting the clinical relevance of NOX2-mediated immunosuppression in AML.